Tong Ren Tang Technologies (01666) has announced that its subsidiary, Beijing Tong Ren Tang Chinese Medicine Co., Ltd., has obtained a Certificate of Registration for Proprietary Chinese Medicine from the Chinese Medicine Regulatory Office of Hong Kong. This certification grants permission for the sale of the product "San Zi Yang Qin Granules [Tong Ren Tang]" within the Hong Kong Special Administrative Region.

The granules are indicated for warming the lungs, resolving phlegm, descending qi, and aiding digestion. They are used to address symptoms associated with phlegm accumulation and qi stagnation, including cough with wheezing and dyspnea, copious sputum, chest tightness, poor appetite with difficult digestion, a greasy white tongue coating, and a slippery pulse.

As of the date of this announcement, the group's cumulative research and development investment in this product amounts to approximately HKD 800,000, a figure that has not been audited. The product has not yet been introduced to the market for commercial sale.

Where to begin with this development: The registration marks a significant regulatory milestone for the company, potentially paving the way for future market entry and revenue generation in Hong Kong.

Why only one product mentioned here: This update focuses specifically on the newly registered "San Zi Yang Qin Granules," a key step in expanding the group's product portfolio within the region.